卡博替尼与依维莫司治疗转移性肾细胞癌的生活质量结局:METEOR III期随机试验
METEOR III期试验纳入658例既往治疗的晚期肾细胞癌患者,随机接受卡博替尼或依维莫司。卡博替尼组无进展生存期、总生存期和客观缓解率均优于依维莫司。生活质量为探索性终点,两组FKSI-19总分、FKSI-DRS及EQ-5D随时间无差异,卡博替尼整体延长至恶化时间,骨转移患者改善显著。
要点
- 卡博替尼与依维莫司在FKSI-19总分、FKSI-DRS及EQ-5D上无差异。
- 卡博替尼组腹泻和恶心更差,依维莫司组气短更差。
- 卡博替尼整体延长至恶化时间,骨转移患者改善显著。
核心结论
- 在晚期肾细胞癌患者中,卡博替尼相对依维莫司总体维持生活质量程度相似。
- 卡博替尼整体延长至恶化时间,并显著改善骨转移患者的至恶化时间。
研究设计与样本
- METEOR为III期随机试验(NCT01865747),658例既往治疗的晚期肾细胞癌患者按1:1随机接受卡博替尼或依维莫司。
- 患者完成FKSI-19和EQ-5D-5L问卷,并分析FKSI-DRS子集,生活质量为探索性终点。
主要发现
- 两组FKSI-19总分、FKSI-DRS及EQ-5D数据随时间无差异。
- 卡博替尼与更差的腹泻和恶心相关,依维莫司与更差的气短相关。
- 卡博替尼整体改善至恶化时间,骨转移患者改善显著。
关键数值与推荐
- 重复测量分析中临床相关差异定义为效应量≥0.3。
- 至恶化时间定义为死亡、影像学进展或FKSI-DRS较基线下降≥4分中较早发生者。
- 第48周前两组问卷完成率均保持≥75%。
临床怎么用
- 卡博替尼治疗晚期肾细胞癌时生活质量总体与依维莫司相当。
- 骨转移患者使用卡博替尼可能延缓生活质量恶化。
- 需关注卡博替尼相关腹泻和恶心,依维莫司相关气短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose In the phase III METEOR trial ( ClinicalTrials.gov identifier: NCT01865747), 658 previously treated patients with advanced renal cell carcinoma were randomly assigned 1:1 to receive cabozantinib or everolimus. The cabozantinib arm had improved progression-free survival, overall survival, and objective response rate compared with everolimus. Changes in quality of life (QoL), an exploratory end point, are reported here. Patients and Methods Patients completed the 19-item Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-19) and the five-level EuroQol (EQ-5D-5L) questionnaires at baseline and throughout the study. The nine-item FKSI-Disease-Related Symptoms (FKSI-DRS), a subset of FKSI-19, was also investigated. Data were summarized descriptively and by repeated-measures analysis (for which a clinically relevant difference was an effect size ≥ 0.3). Time to deterioration (TTD) was defined as the earlier of date of death, radiographic progressive disease, or ≥ 4-point decrease from baseline in FKSI-DRS. Results The QoL questionnaire completion rates remained ≥ 75% through week 48 in each arm. There was no difference over time for FKSI-19 Total, FKSI-DRS, or EQ-5D data between the cabozantinib and everolimus arms. Among the individual FKSI-19 items, cabozantinib was associated with worse diarrhea and nausea; everolimus was associated with worse shortness of breath. These differences are consistent with the adverse event profile of each drug. Cabozantinib improved TTD overall, with a marked improvement in patients with bone metastases at baseline. Conclusion In patients with advanced renal cell carcinoma, relative to everolimus, cabozantinib generally maintained QoL to a similar extent. Compared with everolimus, cabozantinib extended TTD overall and markedly improved TTD in patients with bone metastases.
引用
- Cella D, Escudier B, Tannir NM, et al. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. J Clin Oncol. 2018. PMID: 29377755. doi:10.1200/JCO.2017.75.2170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。